Aligos Therapeutics, Inc. (ALGS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
13/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseALGS / S&P -22.34% / 15.20% |
WinALGS / S&P 19.41% / 15.00% |
LoseALGS / S&P -62.65% / 50.40% |
| 2026-Q11/3 |
LoseALGS / S&P -20.28% / -4.33% |
WinALGS / S&P 45.76% / 11.30% |
LoseALGS / S&P -49.69% / 27.70% |
| 2025-Q40/3 |
LoseALGS / S&P -4.90% / 2.65% |
LoseALGS / S&P -39.46% / 9.00% |
LoseALGS / S&P -58.50% / 13.40% |
| 2025-Q32/3 |
WinALGS / S&P 35.92% / 8.12% |
LoseALGS / S&P -28.66% / 4.61% |
WinALGS / S&P 165.50% / 13.45% |
| 2025-Q21/3 |
LoseALGS / S&P -12.61% / 10.94% |
LoseALGS / S&P -10.82% / 4.83% |
WinALGS / S&P 34.31% / 10.63% |
| 2025-Q10/3 |
LoseALGS / S&P -79.29% / -4.27% |
LoseALGS / S&P -52.14% / 4.98% |
LoseALGS / S&P 9.26% / 10.57% |
| 2024-Q42/3 |
WinALGS / S&P 360.05% / 2.41% |
LoseALGS / S&P -41.67% / 5.25% |
WinALGS / S&P 91.41% / 6.15% |
| 2024-Q30/3 |
LoseALGS / S&P -1.03% / 5.89% |
LoseALGS / S&P -33.38% / 5.89% |
LoseALGS / S&P -37.08% / 6.11% |
| 2024-Q21/3 |
LoseALGS / S&P -64.29% / 4.28% |
LoseALGS / S&P -20.79% / 5.38% |
WinALGS / S&P 672.25% / 5.12% |
| 2024-Q13/3 |
WinALGS / S&P 47.59% / 10.56% |
WinALGS / S&P 4717.86% / 5.71% |
WinALGS / S&P 720.00% / 5.59% |
| 2023-Q41/3 |
LoseALGS / S&P -11.11% / 11.69% |
LoseALGS / S&P ALGS unavailable / 6.81% |
WinALGS / S&P 384.07% / 7.78% |
| 2023-Q30/3 |
LoseALGS / S&P -23.07% / -3.27% |
LoseALGS / S&P ALGS unavailable / 7.52% |
LoseALGS / S&P ALGS unavailable / -5.03% |
| 2023-Q21/3 |
WinALGS / S&P 11.10% / 8.74% |
LoseALGS / S&P ALGS unavailable / 9.50% |
LoseALGS / S&P ALGS unavailable / -8.57% |
| 2023-Q10/3 |
LoseALGS / S&P -8.29% / 7.50% |
LoseALGS / S&P ALGS unavailable / 10.77% |
LoseALGS / S&P ALGS unavailable / -15.69% |
| 2022-Q40/3 |
LoseALGS / S&P -13.36% / 7.56% |
LoseALGS / S&P ALGS unavailable / 11.88% |
LoseALGS / S&P ALGS unavailable / -17.99% |
| 2022-Q30/3 |
LoseALGS / S&P -9.09% / -4.88% |
LoseALGS / S&P ALGS unavailable / 13.47% |
LoseALGS / S&P ALGS unavailable / -1.41% |
| 2022-Q20/3 |
LoseALGS / S&P -43.72% / -16.10% |
LoseALGS / S&P ALGS unavailable / 13.71% |
LoseALGS / S&P ALGS unavailable / 11.04% |
| 2022-Q10/3 |
LoseALGS / S&P -81.89% / -4.60% |
LoseALGS / S&P ALGS unavailable / 15.97% |
LoseALGS / S&P ALGS unavailable / 42.23% |
| 2021-Q40/3 |
LoseALGS / S&P -23.47% / 11.03% |
LoseALGS / S&P ALGS unavailable / 15.00% |
LoseALGS / S&P ALGS unavailable / 96.40% |
| 2021-Q30/3 |
LoseALGS / S&P -23.91% / 0.58% |
LoseALGS / S&P ALGS unavailable / 10.77% |
LoseALGS / S&P ALGS unavailable / 69.42% |
| 2021-Q20/3 |
LoseALGS / S&P -10.36% / 8.55% |
LoseALGS / S&P ALGS unavailable / 6.58% |
LoseALGS / S&P ALGS unavailable / 51.81% |
| 2021-Q10/3 |
LoseALGS / S&P -17.76% / 6.17% |
LoseALGS / S&P ALGS unavailable / -1.06% |
LoseALGS / S&P ALGS unavailable / 7.39% |
| 2020-Q40/3 |
LoseALGS / S&P ALGS unavailable / 12.15% |
LoseALGS / S&P ALGS unavailable / -3.72% |
LoseALGS / S&P ALGS unavailable / -33.42% |
| 2020-Q30/3 |
LoseALGS / S&P ALGS unavailable / 8.93% |
LoseALGS / S&P ALGS unavailable / -2.04% |
LoseALGS / S&P ALGS unavailable / -27.10% |
| 2020-Q20/3 |
LoseALGS / S&P ALGS unavailable / 20.54% |
LoseALGS / S&P ALGS unavailable / -0.46% |
LoseALGS / S&P ALGS unavailable / -27.11% |
| 2020-Q10/3 |
LoseALGS / S&P ALGS unavailable / -19.60% |
LoseALGS / S&P ALGS unavailable / 3.47% |
LoseALGS / S&P ALGS unavailable / -14.75% |
| 2019-Q40/3 |
LoseALGS / S&P ALGS unavailable / 9.07% |
LoseALGS / S&P ALGS unavailable / 5.36% |
LoseALGS / S&P ALGS unavailable / 2.99% |
| 2019-Q30/3 |
LoseALGS / S&P ALGS unavailable / 1.70% |
LoseALGS / S&P ALGS unavailable / 5.02% |
LoseALGS / S&P ALGS unavailable / 0.21% |
| 2019-Q20/3 |
LoseALGS / S&P ALGS unavailable / 4.30% |
LoseALGS / S&P ALGS unavailable / 6.64% |
LoseALGS / S&P ALGS unavailable / 8.65% |
| 2019-Q10/3 |
LoseALGS / S&P ALGS unavailable / 13.65% |
LoseALGS / S&P ALGS unavailable / 8.12% |
LoseALGS / S&P ALGS unavailable / 14.29% |
| 2018-Q40/3 |
LoseALGS / S&P ALGS unavailable / -13.52% |
LoseALGS / S&P ALGS unavailable / 9.05% |
LoseALGS / S&P ALGS unavailable / 18.23% |
| 2018-Q30/3 |
LoseALGS / S&P ALGS unavailable / 7.71% |
LoseALGS / S&P ALGS unavailable / 10.21% |
LoseALGS / S&P ALGS unavailable / 19.06% |
| 2018-Q20/3 |
LoseALGS / S&P ALGS unavailable / 3.43% |
LoseALGS / S&P ALGS unavailable / 9.03% |
LoseALGS / S&P ALGS unavailable / 14.46% |
| 2018-Q10/3 |
LoseALGS / S&P ALGS unavailable / -0.76% |
LoseALGS / S&P ALGS unavailable / 7.68% |
LoseALGS / S&P ALGS unavailable / 12.46% |
| 2017-Q40/3 |
LoseALGS / S&P ALGS unavailable / 6.64% |
LoseALGS / S&P ALGS unavailable / 7.03% |
LoseALGS / S&P ALGS unavailable / 13.82% |
| 2017-Q30/3 |
LoseALGS / S&P ALGS unavailable / 4.48% |
LoseALGS / S&P ALGS unavailable / 5.68% |
LoseALGS / S&P ALGS unavailable / 17.57% |
| 2017-Q20/3 |
LoseALGS / S&P ALGS unavailable / 3.09% |
LoseALGS / S&P ALGS unavailable / 4.83% |
LoseALGS / S&P ALGS unavailable / 17.74% |
| 2017-Q10/3 |
LoseALGS / S&P ALGS unavailable / 6.07% |
LoseALGS / S&P ALGS unavailable / 3.67% |
LoseALGS / S&P ALGS unavailable / 13.32% |
| 2016-Q40/3 |
LoseALGS / S&P ALGS unavailable / 3.82% |
LoseALGS / S&P ALGS unavailable / 2.09% |
LoseALGS / S&P ALGS unavailable / 7.05% |
| 2016-Q30/3 |
LoseALGS / S&P ALGS unavailable / 3.85% |
LoseALGS / S&P ALGS unavailable / 0.20% |
LoseALGS / S&P ALGS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ALGS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -32.99% | 20.78% |
| Annualized return | -32.99% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ALGS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.30% | 83.14% |
| Annualized return | -55.71% | 12.86% |
10Y · 2020-10-16 to 2026-08-27
| Metric | ALGS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.10% | 319.30% |
| Annualized return | -32.71% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |